Bruno C Odisio1, Aaron Ashton2, Yuanqing Yan3, Wei Wei3, Ahmed Kaseb4, Michael J Wallace5, Jean N Vauthey6, Sanjay Gupta5, Alda L Tam5. 1. Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, Houston, TX 77030-3722. Electronic address: bcodisio@mdanderson.org. 2. Department of Diagnostic Radiology (A.A.), The University of Texas Medical School at Houston, Houston, Texas. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, Houston, TX 77030-3722. 4. Department of Gastrointestinal (GI), Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, Houston, TX 77030-3722. 5. Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, Houston, TX 77030-3722. 6. Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, Houston, TX 77030-3722.
Abstract
PURPOSE: To assess the incidence and severity of adverse events (AEs) in the form of clinical symptoms and liver/biliary injuries (LBI) in patients with hepatic malignancies treated with transarterial chemoembolization using 70-150 μm drug-eluting beads (DEBs). MATERIALS AND METHODS: A single-institution retrospective analysis was performed in 37 patients (25 patients with hepatocellular carcinoma and 12 patients with metastatic disease) who underwent 43 sessions of segmental/subsegmental 70-150 μm DEB transarterial chemoembolization with doxorubicin (38 sessions) or irinotecan (5 sessions). Patient inclusion criteria included the presence of the following lesion features: small diameter (≤ 3 cm), hypovascular, or with areas of residual disease after other locoregional therapies. Mean tumor diameter was 3.4 cm. Mean imaging and clinical follow-up periods were 171 days and 373 days, respectively. Clinical, laboratory, and imaging data were used to identify and classify clinically symptomatic AEs per session and LBI per patient according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Predictors for the occurrence of LBI were evaluated by logistic regression analysis. RESULTS: No grade 4 or 5 AEs were recorded. Clinically symptomatic AEs occurred in 29 (67.4%) sessions (grade 1-2, 28 sessions; grade 3, 1 session), all constituting postembolization syndrome. Asymptomatic LBI occurred in 11 (29.7%) patients (grade 1, 8 patients; grade 2, 3 patients). The mean time between 70-150 μm DEB transarterial chemoembolization session and appearance of LBI was 71 days (range, 21-223 d). No predictive factors for the development of LBI were identified. CONCLUSIONS: Transarterial chemoembolization with 70-150 μm DEBs was considered safe in the present study population given the acceptably low incidence and severity of AEs.
PURPOSE: To assess the incidence and severity of adverse events (AEs) in the form of clinical symptoms and liver/biliary injuries (LBI) in patients with hepatic malignancies treated with transarterial chemoembolization using 70-150 μm drug-eluting beads (DEBs). MATERIALS AND METHODS: A single-institution retrospective analysis was performed in 37 patients (25 patients with hepatocellular carcinoma and 12 patients with metastatic disease) who underwent 43 sessions of segmental/subsegmental 70-150 μm DEB transarterial chemoembolization with doxorubicin (38 sessions) or irinotecan (5 sessions). Patient inclusion criteria included the presence of the following lesion features: small diameter (≤ 3 cm), hypovascular, or with areas of residual disease after other locoregional therapies. Mean tumor diameter was 3.4 cm. Mean imaging and clinical follow-up periods were 171 days and 373 days, respectively. Clinical, laboratory, and imaging data were used to identify and classify clinically symptomatic AEs per session and LBI per patient according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Predictors for the occurrence of LBI were evaluated by logistic regression analysis. RESULTS: No grade 4 or 5 AEs were recorded. Clinically symptomatic AEs occurred in 29 (67.4%) sessions (grade 1-2, 28 sessions; grade 3, 1 session), all constituting postembolization syndrome. Asymptomatic LBI occurred in 11 (29.7%) patients (grade 1, 8 patients; grade 2, 3 patients). The mean time between 70-150 μm DEB transarterial chemoembolization session and appearance of LBI was 71 days (range, 21-223 d). No predictive factors for the development of LBI were identified. CONCLUSIONS: Transarterial chemoembolization with 70-150 μm DEBs was considered safe in the present study population given the acceptably low incidence and severity of AEs.
Authors: Andrew L Lewis; M Victoria Gonzalez; Simon W Leppard; Joanna E Brown; Peter W Stratford; Gary J Phillips; Andrew W Lloyd Journal: J Mater Sci Mater Med Date: 2007-05-05 Impact factor: 3.896
Authors: Julien Joskin; Thierry de Baere; Anne Auperin; Lambros Tselikas; Boris Guiu; Geoffroy Farouil; Valérie Boige; David Malka; Sophie Leboulleux; Michel Ducreux; Eric Baudin; Frédéric Deschamps Journal: Cardiovasc Intervent Radiol Date: 2014-05-30 Impact factor: 2.740
Authors: Giorgio Greco; Tommaso Cascella; Antonio Facciorusso; Roberto Nani; Rodolfo Lanocita; Carlo Morosi; Marta Vaiani; Giuseppina Calareso; Francesca G Greco; Antonio Ragnanese; Marco A Bongini; Alfonso V Marchianò; Vincenzo Mazzaferro; Carlo Spreafico Journal: World J Radiol Date: 2017-05-28